U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2000
--------------
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission file number 0-28443
CYTOMEDIX, INC.
- --------------------------------------------------------------------------------
(Name of small business issuer as specified in its charter)
Delaware 23-2958959
- --------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1523 Bowman Road, Suite A, Little Rock, Arkansas 72211
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(501) 225-8400
- --------------------------------------------------------------------------------
Issuer's telephone number
Autologous Wound Therapy, Inc.
- --------------------------------------------------------------------------------
(Former name, former address, and former fiscal year,
if changed since last report)
Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES [X] NO [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
COMMON STOCK, $.0001 PAR VALUE: 10,500,934
AS OF MAY 12, 2000
Transitional Small Business Disclosure Format (check one): YES [ ] NO [X]
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CYTOMEDIX, INC.
Dated: May 24, 2000 /s/ James A. Cour
-----------------------------------
James A. Cour
President and Chief Executive Officer
(Principal Executive Officer)
Dated: May 24, 2000 /s/ Glenn M. Charlesworth
-----------------------------------
Glenn M. Charlesworth
Chief Financial Officer
(Principal Financial and Accounting Officer)
EXHIBIT LIST
*10.1 Securities Purchase Agreement, dated as of January 25, 2000, between
AuTologous Wound Therapy, Inc. and Lancer Offshore, Inc.
*10.2 Form of Securities Purchase Agreement, dated as of March 1, 2000, among
AuTologous Wound Therapy, Inc. and the investor parties thereto
*10.3 Consulting Agreement, dated as of January 12, 2000, between AuTologous
Wound Therapy, Inc. and The Kriegsman Group
*10.4 First Amendment to Consulting Agreement, dated as of February 22, 2000,
between AuTologous Wound Therapy, Inc. and The Kriegsman Group
10.5 Employment Agreement, dated as of March 3, 2000, between AuTologous Wound
Therapy, Inc. and James A. Cour
*10.6 Employment Agreement, dated as of March 3, 2000, between AuTologous Wound
Therapy, Inc. and Robin L. Geller
*10.7 Employment Agreement, dated as of March 3, 2000, between AuTologous Wound
Therapy, Inc. and Christopher J. Caywood
*10.8 Employment Agreement, dated as of March 3, 2000, between AuTologous Wound
Therapy, Inc. and David C. Demarest
*10.9 Lease, dated as of April 19, 2000, between Cytomedix, Inc. and
CarrAmerica Capital Corporation
*99.1 Press Release, dated April 6, 2000
*27 Financial Data Schedule
- --------------------
* Previously filed